Tamio Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tamio Suzuki has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Yasushi Tomita
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
5 shared publicationsKatsuhiko Inagaki
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
4 shared publicationsMichihiro Kono
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
4 shared publicationsShiro Ito
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
4 shared publicationsHiroshi Shimizu
Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
3 shared publicationsNoriyuki Suzuki
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
3 shared publications
Latest Publications
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e21
Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e21
Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e81
Dowling-Degos disease is genetically and clinico-pathologically distinct from reticulate acropigmentation of Kitamura, further confirmation
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e81
Dowling-Degos disease is genetically and clinico-pathologically distinct from reticulate acropigmentation of Kitamura, further confirmation
- 2 October 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 39 (9) , 819-821
Four novel ADAR1 gene mutations in patients with dyschromatosis symmetrica hereditaria
- 2 October 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 39 (9) , 819-821
Four novel ADAR1 gene mutations in patients with dyschromatosis symmetrica hereditaria
- 1 August 2008
- Vol. 70, 97-106
Evaluation of cetirizine hydrochloride-based therapeutic strategy for chronic urticaria.
We investigated the suitability of cetirizine HCl (cetirizine) for the initial treatment of chronic urticaria. A secondary aim was to identify the optimal alternative treatments when switching from this drug to other drugs in patients who are dissatisfied with cetirizine. We started cetirizine at a once-daily dose of 10 mg for 2 weeks and then, depending on the course of symptoms in individual patients, it was either continued, titrated to a higher dose, or switched to other drugs (antihistamines including H2 blockers) for a further 2 weeks. Degrees of patient satisfaction and ratings by physicians were analyzed, as were adverse events. At 2 weeks after the start of treatment, among 74 patients included in the final evaluation 55 (74.3%) expressed satisfaction with cetirizine therapy. Those not satisfied included five (6.7%) who felt drowsy after taking the drug and 14 (18.9%) in whom the drug had not demonstrated adequate efficacy. After optimizing the treatment on a per-patient basis, including switching from cetirizine to other drugs, the percentage satisfied with treatment at 4 weeks was 83.7% (62/74). In the group of patients who were satisfied with the therapy at 2 weeks, attending physicians confirmed that wheals and scratches were significantly alleviated at 2 and 4 weeks, respectively. Adverse effects were mild and uncommon. Cetirizine as an initial treatment for chronic urticaria appears effective and safe. For patients in whom cetirizine fails to satisfactorily alleviate symptoms as well as those who complain of drowsiness, switching to other antihistamine drugs may be an effective strategy.
- 1 August 2008
- Vol. 70, 97-106
Evaluation of cetirizine hydrochloride-based therapeutic strategy for chronic urticaria.
We investigated the suitability of cetirizine HCl (cetirizine) for the initial treatment of chronic urticaria. A secondary aim was to identify the optimal alternative treatments when switching from this drug to other drugs in patients who are dissatisfied with cetirizine. We started cetirizine at a once-daily dose of 10 mg for 2 weeks and then, depending on the course of symptoms in individual patients, it was either continued, titrated to a higher dose, or switched to other drugs (antihistamines including H2 blockers) for a further 2 weeks. Degrees of patient satisfaction and ratings by physicians were analyzed, as were adverse events. At 2 weeks after the start of treatment, among 74 patients included in the final evaluation 55 (74.3%) expressed satisfaction with cetirizine therapy. Those not satisfied included five (6.7%) who felt drowsy after taking the drug and 14 (18.9%) in whom the drug had not demonstrated adequate efficacy. After optimizing the treatment on a per-patient basis, including switching from cetirizine to other drugs, the percentage satisfied with treatment at 4 weeks was 83.7% (62/74). In the group of patients who were satisfied with the therapy at 2 weeks, attending physicians confirmed that wheals and scratches were significantly alleviated at 2 and 4 weeks, respectively. Adverse effects were mild and uncommon. Cetirizine as an initial treatment for chronic urticaria appears effective and safe. For patients in whom cetirizine fails to satisfactorily alleviate symptoms as well as those who complain of drowsiness, switching to other antihistamine drugs may be an effective strategy.
- 1 February 2007
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 127 (2) , 309-311
Ten Novel Mutations of the ADAR1 Gene in Japanese Patients with Dyschromatosis Symmetrica Hereditaria
- 1 February 2007
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 127 (2) , 309-311
Ten Novel Mutations of the ADAR1 Gene in Japanese Patients with Dyschromatosis Symmetrica Hereditaria
- Open Access
- 1 October 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 125 (4) , 715-720
High Frequency of Hermansky–Pudlak Syndrome Type 1 (HPS1) Among Japanese Albinism Patients and Functional Analysis of HPS1 Mutant Protein
- 1 October 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 125 (4) , 715-720
Open AccessHigh Frequency of Hermansky–Pudlak Syndrome Type 1 (HPS1) Among Japanese Albinism Patients and Functional Analysis of HPS1 Mutant Protein
- Open Access
- 1 June 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 124 (6) , 1186-1192
Mutation Analysis of the ADAR1 Gene in Dyschromatosis Symmetrica Hereditaria and Genetic Differentiation from both Dyschromatosis Universalis Hereditaria and Acropigmentatio Reticularis
- 1 June 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 124 (6) , 1186-1192
Open AccessMutation Analysis of the ADAR1 Gene in Dyschromatosis Symmetrica Hereditaria and Genetic Differentiation from both Dyschromatosis Universalis Hereditaria and Acropigmentatio Reticularis
- 17 January 2005
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 152 (1) , 174-175
A Korean case of oculocutaneous albinism type IV caused by a D157N mutation in theMATPgene
- 17 January 2005
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 152 (1) , 174-175
A Korean case of oculocutaneous albinism type IV caused by a D157N mutation in theMATPgene
- 1 March 2004
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 74 (3) , 466-471
Oculocutaneous Albinism Type 4 Is One of the Most Common Types of Albinism in Japan
- 1 March 2004
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 74 (3) , 466-471
Oculocutaneous Albinism Type 4 Is One of the Most Common Types of Albinism in Japan
- 1 May 2003
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 120 (5) , 781-783
Six Novel P Gene Mutations and Oculocutaneous Albinism Type 2 Frequency in Japanese Albino Patients
- 1 May 2003
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 120 (5) , 781-783
Six Novel P Gene Mutations and Oculocutaneous Albinism Type 2 Frequency in Japanese Albino Patients